Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03454022 · ClinicalTrials.gov registry record · NA

Decision-Aid for Renal Therapy Pilot Trial

A NA study, sponsored by Tufts University.

Completed
Registry status
NA
Development phase
31
Enrollment target

NCT03454022: Completed NA study, sponsored by Tufts University.

NCT03454022 is a NA study that has completed, run by Tufts University. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03454022, a NA study, has completed, sponsored by Tufts University.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target

Study Summary

Successful communication between patients, caregivers, and physicians can improve how patients feel about their treatment. Our recent studies of older dialysis patients find, however, that many patients do not engage in this type of communication about treatment options. This study aims to determine whether the Decision-Aid for Renal Therapy (DART), a web-based program, can improve shared decision-making (decisions where patients are actively engaged) among patients, caregivers, and physicians, and improve certainty and satisfaction in treatment decisions.

Primary Outcome

Participants will be asked if they have completed an advance directive.

Interventions

  • BEHAVIORAL DART
  • BEHAVIORAL Choosing a Treatment for Kidney Failure

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2017-03-16
Est. Completion 2018-07-01
Phase NA
Tufts University

163 total trials

What the finished NCT03454022 record still lists

NCT03454022 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which DART is the first listed.

NCT03454022 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03454022 about?

NCT03454022 is a clinical study titled "Decision-Aid for Renal Therapy Pilot Trial". Successful communication between patients, caregivers, and physicians can improve how patients feel about their treatment. Our recent studies of older dialysis patients find, however, that many patients do not engage in this type of communication about treatment options. This study aims to determine...

What is the current status of trial NCT03454022?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2017-03-16. Estimated completion is 2018-07-01.

What interventions are being tested in trial NCT03454022?

The interventions under investigation include: DART (BEHAVIORAL), Choosing a Treatment for Kidney Failure (BEHAVIORAL).

Who is sponsoring clinical trial NCT03454022?

This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03454022's enrollment target sits among peer trials

31 1592nd of 2000 higher than 408 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03454022, the US trial registry maintained by the National Library of Medicine. NCT03454022 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.